Ocrelizumab extended dosing in Primary Progressive Multiple Sclerosis during the COVID-19 pandemic: a multicenter experience

被引：0
|
作者：
D'Amico, E. [1 ]
Avolio, C. [1 ]
Lus, G. [2 ]
Bonavita, S. [3 ]
Ferraro, D. [4 ]
Callari, G. [5 ]
Barone, S. [6 ]
Patti, F. [7 ]
Granella, F. [8 ]
Zanghi, A. [9 ]
机构：
[1] Univ Foggia, Foggia, Italy
[2] Univ Campania Luigi Vanvitelli, Naples, Italy
[3] Univ Naples Federico II, Naples, Italy
[4] Univ Modena, Modena, Italy
[5] Irccs Cefalu, Cefalu, Italy
[6] Univ Catanzaro, Catanzaro, Italy
[7] Uni Catania, Catania, Italy
[8] Univ Parma, Parma, Italy
[9] Sant Elia Hosp, Caltanissetta, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1246
引用
下载
收藏
页码：1007 / 1008
页数：2
相关论文
共 50 条
  • [41] The COVID-19 Pandemic Experience in Multiple Sclerosis: The Good, the Bad and the Neutral
    Hannah Morris-Bankole
    Aileen K. Ho
    Neurology and Therapy, 2021, 10 : 279 - 291
  • [42] Trends and predictors of peripheral CD19+B-cell repopulation in patients treated with extended interval ocrelizumab dosing during COVID-19 pandemic
    Padron, Elizabeth
    Hernandez, Jeffrey
    Tornes, Leticia
    Garg, Neeta
    NEUROLOGY, 2021, 96 (15)
  • [43] Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis REPLY
    Hauser, Stephen L.
    Belachew, Shibeshih
    Kappos, Ludwig
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (17): : 1694 - 1694
  • [44] Multiple sclerosis centers during COVID-19 pandemic: an italian multicenter patient-centered survey
    Risi, M.
    Altieri, M.
    Capuano, R.
    Cavalla, P.
    Vercellino, M.
    Annovazzi, P.
    Zaffaroni, M.
    De Stefano, N.
    Stromillo, M.
    D'Amico, E.
    Buscarinu, M.
    Lanzillo, R.
    De Luca, G.
    Calabrese, M.
    Cocco, E.
    Di Filippo, M.
    Valentino, P.
    Gajofatto, A.
    Marfia, G.
    Fuiani, A.
    Nociti, V.
    Bisecco, A.
    D'Ambrosio, A.
    Tedeschi, G.
    Gallo, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 725 - 725
  • [45] Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
    Montalban, X.
    Hauser, S. L.
    Kappos, L.
    Arnold, D. L.
    Bar-Or, A.
    Comi, G.
    de Seze, J.
    Giovannoni, G.
    Hartung, H. -P.
    Hemmer, B.
    Lublin, F.
    Rammohan, K. W.
    Selmaj, K.
    Traboulsee, A.
    Sauter, A.
    Masterman, D.
    Fontoura, P.
    Belachew, S.
    Garren, H.
    Mairon, N.
    Chin, P.
    Wolinsky, J. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 209 - 220
  • [46] COVID-19 infection and vaccination in patients with multiple sclerosis during COVID pandemic
    Oreja-Guevara, C.
    Martinez-Perez, E.
    Gomez Estevez, I.
    Ramirez, C. I.
    Diaz-Diaz, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 913 - 913
  • [47] Multiple sclerosis patients and the COVID-19 pandemic
    Canzonieri, A. M.
    de Sousa, D.
    de Almeida, B.
    Soares, J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 737 - 738
  • [48] Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
    Schuckmann, Aaron
    Steffen, Falk
    Zipp, Frauke
    Bittner, Stefan
    Pape, Katrin
    MED, 2023, 4 (06): : 361 - +
  • [49] COVID-19 in persons with multiple sclerosis treated with ocrelizumab: pharmacovigilance update
    Hughes, R.
    Fitovski, K.
    Whitley, L.
    Jessop, N.
    Schneble, H-M
    Muros-Le Rouzic, E.
    Sauter, A.
    Pedotti, R.
    Koendgen, H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 49 - 49
  • [50] Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
    Suwanwongse, Kulachanya
    Shabarek, Nehad
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 42
12345